1. Home
  2. KNSA vs RNW Comparison

KNSA vs RNW Comparison

Compare KNSA & RNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • RNW
  • Stock Information
  • Founded
  • KNSA 2015
  • RNW 2011
  • Country
  • KNSA United Kingdom
  • RNW United Kingdom
  • Employees
  • KNSA N/A
  • RNW N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • RNW Electric Utilities: Central
  • Sector
  • KNSA Health Care
  • RNW Utilities
  • Exchange
  • KNSA Nasdaq
  • RNW Nasdaq
  • Market Cap
  • KNSA 2.6B
  • RNW 2.7B
  • IPO Year
  • KNSA 2018
  • RNW N/A
  • Fundamental
  • Price
  • KNSA $41.77
  • RNW $7.51
  • Analyst Decision
  • KNSA Strong Buy
  • RNW Buy
  • Analyst Count
  • KNSA 6
  • RNW 2
  • Target Price
  • KNSA $51.33
  • RNW $7.83
  • AVG Volume (30 Days)
  • KNSA 461.3K
  • RNW 1.5M
  • Earning Date
  • KNSA 10-28-2025
  • RNW 11-10-2025
  • Dividend Yield
  • KNSA N/A
  • RNW N/A
  • EPS Growth
  • KNSA N/A
  • RNW 413.66
  • EPS
  • KNSA 0.47
  • RNW 0.26
  • Revenue
  • KNSA $597,973,000.00
  • RNW $1,382,164,625.00
  • Revenue This Year
  • KNSA $62.63
  • RNW N/A
  • Revenue Next Year
  • KNSA $29.93
  • RNW $16.58
  • P/E Ratio
  • KNSA $89.00
  • RNW $28.73
  • Revenue Growth
  • KNSA 55.68
  • RNW 46.76
  • 52 Week Low
  • KNSA $17.82
  • RNW $5.42
  • 52 Week High
  • KNSA $42.93
  • RNW $8.24
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 64.60
  • RNW 48.50
  • Support Level
  • KNSA $39.61
  • RNW $7.22
  • Resistance Level
  • KNSA $42.93
  • RNW $7.61
  • Average True Range (ATR)
  • KNSA 1.43
  • RNW 0.12
  • MACD
  • KNSA 0.19
  • RNW 0.02
  • Stochastic Oscillator
  • KNSA 79.30
  • RNW 75.00

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About RNW ReNew Energy Global plc

ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.

Share on Social Networks: